scholarly journals Epidermal Growth Factor Signaling and Mitogenesis inPlcg1 Null Mouse Embryonic Fibroblasts

1998 ◽  
Vol 9 (4) ◽  
pp. 749-757 ◽  
Author(s):  
Qun-sheng Ji ◽  
Sandra Ermini ◽  
Josep Baulida ◽  
Feng-lei Sun ◽  
Graham Carpenter
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Receptor Activation ◽  
Mitogen Activated Protein Kinase ◽  
Null Mouse ◽  
Growth Factor Signaling ◽  
Mitogen Activated Protein ◽  
Epidermal Growth ◽  
Early Mouse

Gene targeting techniques and early mouse embryos have been used to produce immortalized fibroblasts genetically deficient in phospholipase C (PLC)-γ1, a ubiquitous tyrosine kinase substrate.Plcg1 −/− embryos die at embryonic day 9; however, cells derived from these embryos proliferate as well as cells from Plcg1 +/+ embryos. The null cells do grow to a higher saturation density in serum-containing media, as their capacity to spread out is decreased compared with that of wild-type cells. In terms of epidermal growth factor receptor activation and internalization, or growth factor induction of mitogen-activated protein kinase, c-fos, or DNA synthesis in quiescent cells, PLcg1 −/− cells respond equivalently to PLcg1 +/+ cells. Also, null cells are able to migrate effectively in a wounded monolayer. Therefore, immortalized fibroblasts do not require PLC-γ1 for many responses to growth factors.

scholarly journals Dok-R Mediates Attenuation of Epidermal Growth Factor-Dependent Mitogen-Activated Protein Kinase and Akt Activation through Processive Recruitment of c-Src and Csk

2005 ◽  
Vol 25 (9) ◽  
pp. 3831-3841 ◽  
Author(s):  
Paul Van Slyke ◽  
Mariano Loza Coll ◽  
Zubin Master ◽  
Harold Kim ◽  
Jorge Filmus ◽  
...  
Keyword(s):  
Growth Factor ◽  
Protein Kinase ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Cancer Cell Line ◽  
Mitogen Activated Protein Kinase ◽  
Structural Determinants ◽  
Mapk Activation ◽  
Mitogen Activated Protein ◽  
Epidermal Growth

ABSTRACT Dok-R has previously been shown to associate with the epidermal growth factor receptor (EGFR) and become tyrosine phosphorylated in response to EGF stimulation. The recruitment of Dok-R to the EGFR, which is mediated through its phosphotyrosine binding (PTB) domain, results in attenuation of mitogen-activated protein kinase (MAPK) activation. Dok-R's ability to attenuate EGF-driven MAPK activation is independent of its ability to recruit rasGAP, a known attenuator of MAPK activity, suggesting an alternate Dok-R-mediated pathway. Herein, we have determined the structural determinants within Dok-R that are required for its ability to attenuate EGF signaling and to associate with c-Src and with the Src family kinase (SFK)-inhibitory kinase, Csk. We demonstrate that Dok-R associates constitutively with c-Src through an SH3-dependent interaction and that this association is essential to Dok-R's ability to attenuate c-Src activity and diminish MAPK and Akt/PKB activity. We further illustrate that EGF-dependent phosphorylation of Dok-R requires SFK activity and, more specifically, that SFK-dependent phosphorylation of tyrosine 402 on Dok-R facilitates the inducible recruitment of Csk. We propose that recruitment of Csk to Dok-R serves to bring Csk to c-Src and down-regulate its activity, resulting in a concomitant attenuation of MAPK and Akt/PKB activity. Furthermore, we demonstrate that Dok-R can abrogate c-Src's ability to protect the breast cancer cell line SKBR3 from anoikis and that an association with c-Src and Csk is required for this activity. Collectively these results demonstrate that Dok-R acts as an EGFR-recruited scaffolding molecule that processively assembles c-Src and Csk to attenuate signaling from the EGFR.

Sign in / Sign up

Export Citation Format

Share Document